Rheumatoid arthritis registries in Sweden

Clinical and Experimental Rheumatology

Volumn 23, Issue 5 SUPPL. 39, 2005, Pages

  Van Vollenhoven, Ronald F ^a   Ashling, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Biologicals; Long term efficacy; Longitudinal studies; Quality control; Registries

Indexed keywords

ANTIRHEUMATIC AGENT; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; MEDICAL RECORD; MONOTHERAPY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REGISTER; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SWEDEN; TREATMENT FAILURE; TREATMENT PLANNING; ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DATA BASE; DISEASE REGISTRY; DRUG EFFICACY; DRUG SAFETY; INTERNATIONAL COOPERATION; LONGITUDINAL STUDY; MEDICAL PRACTICE; PATIENT INFORMATION; PATIENT SAFETY; PHARMACOECONOMICS; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; RHEUMATOLOGY; TREATMENT RESPONSE; VALIDITY; FACTUAL DATABASE; METHODOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; HUMANS; LONGITUDINAL STUDIES; REGISTRIES; RHEUMATOLOGY; SWEDEN;

EID: 33644800929     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. PINCUS T, STEIN CM: Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol 1997; 15: S27-S38.
2. PINCUS T: Limitations of randomized clinical trials in chronic diseases: Explanations and recommendations. Adv Mind Body Med 2002; 18: 14-21.
3. MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
4. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
5. ST CLAIR EW, WAGNER CL, FASANMADE AA et al.: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9.
6. BREEDVELD FC, EMERY P, KEYSTONE E et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004; 63: 149-55.
7. SOKKA T, PINCUS T: Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Arthritis Rheum 2003; 48: 313-8.
8. HEDIN PJ: (Det bidde bara en tummetott). Presented at the 2003 annual scientific meeting of the Swedish Rheumatological Society.
9. WILES NJ, LUNT M, BARRETT EM et al.: Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum 2001; 44: 1033-42.
10. BUKHARI MA, WILES NJ, LUNT M et al.: Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: Results from a large observational inception study. Arthritis Rheum 2003; 48: 46-53.
11. LANDEWE RB: The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 2003; 48: 1-5.
12. FRIES JF: The chronic disease data bank: First principles to future directions. J Med Philos 1984; 16: 161-80.
13. FRIES JF, MCSHANE D: ARAMIS (the American Rheumatism Association Medical Information System). A prototypical national chronic-disease data bank. West J Med 1986; 145: 798-804.
14. SINGH G: Arthritis, Rheumatism and Aging Medical Information System post-marketing surveillance program. J Rheumatol 2001; 28: 1174-9.
15. WOLFE F, REHMAN Q, LANE NE et al.: Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: Standards of practice for RA treatment. J Rheumatol 2001; 28: 1704-11.
16. SYMMONS DP, BARRETT EM, BANKHEAD CR et al.: The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994; 33: 735-9.
17. LINDBLAD S, BENGTSSON A, NORDMARK B et al.: (A pilot project to learn quality development: care of patients with recently diagnosed rheumatic arthritis). Lakartidningen 1999; 96: 2493-6.
18. SEBALDT RJ, KREMER JM: CANDOO and CANOAR, CORRONA and more: Advancing therapeutics through layered-in clinical data collection and feedback at the point of care. J Rheumatol 2003; 30: 2308-11.
19. SILMAN A, SYMMONS D, SCOTT DG et al.: 2003. British Society for Rheumatology Biologics Register. Ann Rheum Dis 2003; 62: ii 28-9.
20. GOMEZ-REINO JJ, CARMONA L, VALVERDE VR et al.: BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003; 48: 2122-7.
21. FANTINI F: (New drugs and treatment strategies for rheumatoid arthritis) Recenti Prog Med 2003; 94: 361-79.
22. ZINK A, HUSCHER D, LISTING J: (The National Database of the Regional Collaborative Rheumatic Centers as a tool for clinical epidemiology and quality assessment in rheumatology). Z Arztl Fortbild Qualitatssich 2003; 97: 399-405.
23. GEBOREK P, CRNKIC M, PETERSSON IF et al.: South Swedish Arthritis Treatment Group: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
24. KOBELT G, EBERHARDT K, GEBOREK P: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann Rheum Dis 2004; 63: 4-10.
25. VAN VOLLENHOVEN RF, KLARESKOG L: Clinical responses to tumor necrosis factor-a antagonists do not show a bimodal distribution. Data from the Stockholm tumor necrosis factor-a registry. Arthritis Rheum 2003; 48: 1500-3.
26. VAN VOLLENHOVEN RF, ERNESTAM S, HARJU A et al.: Etanercept versus etanercept plus methotrexate: A registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003; 5: 347-51.
27. KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
28. VAN VOLLENHOVEN RF, HARJU A, BRANNEMARK S et al.: Treatment with infliximab (Remicade) in patients who failed etanercept (Enbrel) or vice versa: Data from the STURE registry showing that switching TNF-α blockers can make sense. Ann Rheum Dis 2003; 62: 1195-8.
29. ASKLING J, BRANDT L, BERTILSSON L et al.: Risk for lymphomas following TNF-blockade. Comparison with a nationwide comorbidity database. Ann Rheum Dis 2004; 63 (Suppl.): 258.